27 completed, 5 active not recruiting, 3 terminated. 35 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 35 | Completed 27, Active not recruiting 5, Terminated 3 |
| Phase 2 | 6 | Active not recruiting 3, Completed 3 |
Follow cediranib: new trials by email Literature Review of cediranib trials Research Report on cediranib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... Olaparib, Cediranib, Durvalumab - Colorectal Neoplasms, Breast Neoplasms | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 268 | 2015-06-29 | 2026-10-16 |
| Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies Cediranib, Cediranib Maleate, Laboratory Biomarker Analysis - Metastatic Melanoma, Refractory Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 19 | 2011-05-25 | 2026-09-10 |
| Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Cediranib, Cediranib Maleate, Laboratory Biomarker Analysis - Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 127 | 2010-09-09 | 2021-07-15 |
| Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial AZD6244, Cediranib (AZD2171) - Rectal Cancer | Phase 1 | Terminated | The Christie NHS Foundation Trust | 31 | 2010-07-01 | 2023-04-24 |
| Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Gamma-Secretase Inhibitor RO4929097, Cediranib Maleate, Pharmacological Study - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2010-05-01 | 2014-12-23 |
| Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Cediranib Maleate - Fallopian Tube Carcinoma, Ovarian Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 155 | 2010-04-14 | 2026-07-14 |
| Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Cediranib Maleate, Cisplatin, Laboratory Biomarker Analysis - Epithelioid Mesothelioma, Pleural Malignant Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 117 | 2010-03-15 | 2026-10-22 |
| Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma Cediranib Maleate, Cilengitide, Laboratory Biomarker Analysis - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 | Completed | National Cancer Institute (NCI) | 47 | 2010-03-01 | 2015-04-15 |
| AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies temsirolimus, cediranib - Endometrial Cancer, Ovarian Cancer | Phase 1 | Completed | Susana M. Campos, MD | 11 | 2010-02-01 | 2021-04-21 |
| A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies cediranib (RECENTIN TM, AZD2171) - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 20 | 2009-09-01 | 2011-06-20 |
| Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer cediranib maleate, whole-brain radiation therapy - Male Breast Cancer, Stage IV Breast Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 18 | 2009-08-01 | 2013-03-08 |
| Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients Cediranib, Cisplatin, S-1 - Gastric Cancer | Phase 1 | Completed | AstraZeneca | 14 | 2009-08-01 | 2011-06-14 |
| Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours cediranib - Solid Tumors | Phase 1 | Active not recruiting | AstraZeneca | 64 | 2008-09-09 | 2026-08-17 |
| Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours cediranib (RECENTIN TM, AZD2171) - Advanced Solid Tumors | Phase 1 | Completed | AstraZeneca | 46 | 2008-08-01 | 2011-03-10 |
| DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study) Recentin (Cediranib) - Cancer | Phase 1 | Completed | AstraZeneca | 35 | 2008-08-01 | 2011-07-01 |
| Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Cediranib Maleate, Diffusion Tensor Imaging, Diffusion Weighted Imaging - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 46 | 2008-04-01 | 2023-06-06 |
| Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients AZD2171, Etoposide, Cisplatin - Lung Cancer | Phase 1 | Completed | AstraZeneca | 62 | 2008-02-01 | 2012-12-17 |
| Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours AZD2171 - Advanced Cancer, Hepatic Impairment | Phase 1 | Completed | AstraZeneca | 36 | 2008-01-01 | 2014-07-15 |
| Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients AZD2171, Paclitaxel, Carboplatin - Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | AstraZeneca | 6 | 2007-09-01 | 2011-06-01 |
| Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour Cediranib, Lomustine - Recurrent Glioblastoma, Brain Tumor | Phase 1 | Completed | AstraZeneca | 20 | 2007-09-01 | 2009-11-25 |
Showing 20 of 35. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (6) · Colonic Neoplasms (5) · Neoplasm Metastasis (5) · Rectal Neoplasms (5) · Brain Neoplasms (4) · Breast Neoplasms (4) · Colorectal Neoplasms (4) · Glioblastoma (4) · Lung Neoplasms (4) · Neoplasms (4) · Gliosarcoma (3) · Melanoma (3) · Ovarian Neoplasms (3) · Astrocytoma (2) · Breast Neoplasms, Male (2)
AstraZeneca (19) · National Cancer Institute (NCI) (12) · NCIC Clinical Trials Group (2) · Susana M. Campos, MD (1) · The Christie NHS Foundation Trust (1)
United States (17) · Canada (6) · United Kingdom (5) · Japan (4) · Denmark (2) · Germany (2) · Netherlands (2) · China (1) · Spain (1)
Jane Robertson (5) · Nick Botwood, BSc, MBBS, MRCP, MFPM (5) · Jane Roberston (2) · Anne S Tsao (1) · April Eichler (1) · Bijoyesh Mookerjee, MD (1) · Brian A Costello (1) · Brigitte C Widemann, M.D. (1) · Chih-Yi Liao (1) · David Hong (1) · Derek Jonker, MD (1) · Dieter Hoelzer, MD, PhD (1) · Dr U Lassen, MD PhD (1)
PMID 18398152, PMID 19228749, PMID 21060028, PMID 22891356, PMID 23197081, PMID 23810467, PMID 24309981, PMID 25113840, PMID 25218906, PMID 30514390, PMID 31345267, PMID 31386610, PMID 33842889, PMID 37185961, PMID 38197800, PMID 38270822, PMID 41360639, PMID 41881502, PMID 42386344, PMID 42820295
N01CM00071 (2), P30CA006516 (2), U01CA062490 (2), 2008 (1), 2009 (1), N01CM00032 (1), N01CM00038 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1), P30CA014599 (1), P30CA015083 (1), P30CA016672 (1), R01CA129371 (1), U01CA062461 (1)